- Home
- KOD vs IVVD Comparison
KOD vs IVVD Comparison
Compare KOD & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- IVVD
- Stock Information
- Founded
- KOD 2009
- IVVD 2020
- Country
- KOD United States
- IVVD United States
- Employees
- KOD N/A
- IVVD N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- IVVD Health Care
- Exchange
- KOD Nasdaq
- IVVD Nasdaq
- Market Cap
- KOD 148.9M
- IVVD 101.7M
- IPO Year
- KOD 2018
- IVVD 2021
- Fundamental
- Price
- KOD $3.30
- IVVD $1.05
- Analyst Decision
- KOD Hold
- IVVD Strong Buy
- Analyst Count
- KOD 5
- IVVD 4
- Target Price
- KOD $3.25
- IVVD $9.50
- AVG Volume (30 Days)
- KOD 167.4K
- IVVD 427.2K
- Earning Date
- KOD 11-12-2024
- IVVD 11-07-2024
- Dividend Yield
- KOD N/A
- IVVD N/A
- EPS Growth
- KOD N/A
- IVVD N/A
- EPS
- KOD N/A
- IVVD N/A
- Revenue
- KOD N/A
- IVVD $2,264,000.00
- Revenue This Year
- KOD N/A
- IVVD N/A
- Revenue Next Year
- KOD N/A
- IVVD $72.22
- P/E Ratio
- KOD N/A
- IVVD N/A
- Revenue Growth
- KOD N/A
- IVVD N/A
- 52 Week Low
- KOD $1.37
- IVVD $0.81
- 52 Week High
- KOD $7.77
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- KOD 76.62
- IVVD 53.76
- Support Level
- KOD $2.54
- IVVD $0.93
- Resistance Level
- KOD $2.93
- IVVD $1.05
- Average True Range (ATR)
- KOD 0.15
- IVVD 0.09
- MACD
- KOD 0.06
- IVVD 0.01
- Stochastic Oscillator
- KOD 100.00
- IVVD 54.86
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.